Autogenous Demineralized Dentin Graft With High Molecular Weight Hyaluronic Acid in Ridge Preservation: Pilot Trial
Abstract
Objective: The current trial assessed for the first time radiographic and histological alterations, following alveolar ridge preservation (ARP), using autogenous demineralized dentin graft carried in 0.2% high molecular weight sodium hyaluronate (ADDG+HA; test group) versus autogenous demineralized dentin graft (ADDG, control group) alone.
Material and methods: Thirty patients (n = 30) with non-restorable single-rooted teeth were randomly assigned into two groups (n = 15/group). Following extraction, ARP was performed using either ADDG solely or ADDG+HA. Bucco-lingual alveolar ridge width (BLRW; primary outcome), buccal (BRH) and lingual ridge height (LRH), percentage of newly formed bone, soft tissue and residual graft in human biopsies histologically, as well as patients' pain and discomfort (all secondary outcomes) were assessed after 6 months at the time of implant placement. Sample bone core biopsies were further collected, processed, and histomorphometrically and SEM analyzed.
Results: For the ADDG and ADDG+HA groups, the alveolar ridge dimensional changes were comparable, being -1.21 ± 0.77 mm and -1.18 ± 0.86 mm in BLRW, -0.89 ± 0.74 and -0.83 ± 0.85 mm in BRH, and -0.9 ± 0.76 mm and -1.05 ± 1.18 mm in LRH respectively (p > 0.05). Clinically, no complications, pain, or inflammatory responses were reported. Histologically, all samples demonstrated bone growth and socket bone fill, while the ADDG+HA group showed a significantly greater presence of mineralized mature…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 30 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.